<DOC>
	<DOCNO>NCT02184442</DOCNO>
	<brief_summary>The purpose post approval study determine safety , effectiveness learn curve SAPIEN™ THV Retroflex delivery system Inoperable Patients SAPIEN™ THV Retroflex Ascendra delivery system high risk operable patient Severe Symptomatic Native Aortic Stenosis via access site .</brief_summary>
	<brief_title>The PARTNER TRIAL - Post Approval Study Part II</brief_title>
	<detailed_description>The following concern address trial : 1 ) long term ( 5 year ) valve implant durability echocardiography , 2 ) long-term ( 5 year ) quality life assessment KCCQ-12 instrument , 3 ) assessment learn curve post approval setting ( utilize VARC composite procedural success benchmark ) , 4 ) assessment adherence label indication post approval setting ( use assessment baseline characteristic ) 5 ) assessment stroke post approval setting . Study patient undergo clinical follow-up discharge , 30 day , 1 year annually minimum 5 year ( TVT national registry-CMS Linkage ) .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<criteria>Patients must meet fundamental enrollment criterion severe , symptomatic , calcific aortic stenosis quantifiable document source record Upon meet eligibility criterion , heart team shall determine patient 's risk operative morbidity mortality Details eligibility include contraindication provide product Instructions Use include SAPIEN™ THV delivery system .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SAPIEN</keyword>
	<keyword>TAVR</keyword>
	<keyword>THV</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Heart Valve Disease</keyword>
	<keyword>Aortic Valve</keyword>
	<keyword>Retroflex</keyword>
	<keyword>Ascendra</keyword>
</DOC>